secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001213900-23-041332
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics updates Symphony IL-6 regulatory strategy, expands trial to sepsis patients
--------------------------------------------------------------------------------

- Trial widened from severe COVID-19 only to all hospitalized sepsis patients to speed enrollment while maintaining H1 2024 submission timeline.
- Company to submit FDA pre-submission application for revised study design in Q2 2023.
- New indication for risk stratification of hospitalized sepsis patients aligns with recent FDA feedback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023041332/0001213900-23-041332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023041332/ea178902-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-041332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer